Close Menu
Advertisement
Subscribe
[the_ad id="32629"]
Acute Lymphoblastic Leukemia

Idelalisib + Rituximab Successful in Frontline with Some Toxicity

Editor By No Comments1 Min Read

Susan M. OBrien, MD Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research UC Irvine discusses how Idelalisib + Rituximab is Successful in Frontline but with Some Toxicity

Share.

Related Posts